| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $13.3M | -8.2% | -28.8% |
| SG&A Expense | $7.9M | -8.0% | -8.6% |
| Operating Income | -$21.2M | +8.1% | +22.4% |
| Net Income | -$45.5M | -93.4% | -80.8% |
| EPS (Basic) | -$0.87 | -42.6% | +2.2% |
| EPS (Diluted) | -$0.87 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $36.6M | +50.2% | +68.6% |
| Short-term Investments | $14.2M | -38.6% | -77.4% |
| Accounts Receivable | $979K | +16.5% | -47.5% |
| Current Assets | $55.2M | +4.7% | -39.6% |
| Total Assets | $69.4M | +1.7% | -35.2% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$69.3M | — | — |
| Capital Expenditures | $158K | — | — |
| Investing Cash Flow | $14.1M | — | — |
| Financing Cash Flow | $25.9M | — | — |
| Free Cash Flow | -$69.4M | — | — |
| +2.2% |
| $69.8M |
| +120.2% |
| +197.1% |
| Total Liabilities | $77.1M | +94.2% | +130.0% |
| Stockholders' Equity | -$7.7M | -127.1% | -110.5% |